China’s CICC Capital Leads $286M Round In Concord Medical Services Subsidiary

Chinese specialty hospital management solution provider Concord Medical Services Holdings Limited (NYSE: CCM), has announced that CICC Capital Management Company Limited, a wholly-owned subsidiary of China International Capital Corporation Limited, will lead a strategic investment of between RMB1.5 billion (US$238.5 million) and RMB1.8 billion (US$286.16 million) in Concord Medical’s subsidiary Beijing Meizhong Jiahe Hospital Management Co., Ltd. 

Chinese Cell Therapy Firm JW Therapeutics Closes $90 Million Series A Financing

Chinese cell therapy company JW Therapeutics (Shanghai) Co., Ltd announced that it has raised a US$90 million series A found led by investors Temasek, Sequoia Capital China, and YuanMing Capital, a Beijing-based US dollar fund focusing on investments in pharmaceutical research and development, medical devices and services in both China and the U.S.

C-Bridge Capital, BioBAY Lead $38M Series A Round In Biopharmaceutical Service Firm CMAB BioPharm

Chinese private equity firm C-Bridge Capital has teamed up with Suzhou bio-medical and medical high-tech park BioBAY in leading a US$38 million series A round in CMAB BioPharm, a contract development and manufacturing organization (CDMO) providing comprehensive pharmaceutical services to biopharma companies.

China’s Ping An Capital Leads $121M In Singapore’s Fullerton Healthcare

Ping An Capital, the core equity investment platform of one of the largest Chinese insurers Ping An Insurance Group, has led an over RMB800 million (US$121 million) investment deal in Fullerton Healthcare Corporation Ltd., a Singapore-based provider of corporate healthcare solutions across Asia Pacific, according to an announcement issued by Fullerton Healthcare.

KPCB’s James Huang Says High Healthcare Valuations Force Investors To Seek Early Stage Innovation

China’s healthcare sector is seeing a flood of new capital from from non-professional investors such as Chinese coal mining and factory bosses, according to James Huang, a managing partner at Kleiner Perkins Caufield & Byers (KPCB) China, who focuses on life sciences. As a result, valuations have become excessive, forcing more experienced investors to adopt new strategies to get ahead of the "dumb money."

Elements Capital, WI Harper Lead $17.5M Series B Round In Chinese Biopharma Firm

XW Laboratories Inc., a Chinese biopharmaceutical research and development company focused on neurological disorders, has raised US$17.5 million in a series B financing led by Elements Capital and WI Harper. New investo KTB Network, and all existing investors KPCB China, Johnson & Johnson Innovation and WuXi Venture, also participated.